Locally Advanced Cervical Cancer: Outcomes With Variable Adherence to Treatment

Objective: Adherence to treatment regimen and schedule is recommended to improve control of disease and overall survival (OS) in locally advanced cervical cancer. However, treatment-related toxicities and patient and physician factors all impact timely completion of treatment. We sought to correlate adherence to treatment plan with survival and toxicities of patients treated for locally advanced cervical cancer. Materials and Methods: A retrospective review of patients treated for advanced cervical cancer at our institution between 2003 and 2011 was performed. Demographics, clinicopathologic variables, treatment, and disease outcomes were collected. Endpoints of disease outcome were disease-free survival and OS. Statistical analyses were performed using the Kaplan-Meier method, log-rank test, and Cox regression analysis. Results: A total of 162 patients met the inclusion criteria and were included in study analysis. A total of 95% of patients were treated with both radiation and concurrent chemotherapy. Mean radiation dose to point A was 72 Gy. In total, 77% had complete response to primary therapy. Severe (grade 3/4) late radiation toxicities were seen in 10.5% of patients. Stage and total radiation dose to point A were significant predictors of survival for the entire cohort. Among patients receiving at least 72 Gy and brachytherapy, duration of treatment was significantly associated with both disease-free survival and OS. Conclusions: Adherence to both optimal treatment time and radiation dose is significantly associated with improved survival. Total radiation dose is an independent predictor of survival among patients with locally advanced cervical cancer.

[1]  P. Schiff,et al.  Surveillance Epidemiology and End Results Analysis Demonstrates Improvement in Overall Survival for Cervical Cancer Patients Treated in the Era of Concurrent Chemoradiotherapy , 2015, Front. Oncol..

[2]  S. Beriwal,et al.  National Cancer Data Base analysis of radiation therapy consolidation modality for cervical cancer: the impact of new technological advancements. , 2014, International journal of radiation oncology, biology, physics.

[3]  M. Plummer,et al.  Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. , 2013, European journal of cancer.

[4]  Anthony Fyles,et al.  Trends in the utilization of brachytherapy in cervical cancer in the United States. , 2013, International journal of radiation oncology, biology, physics.

[5]  D. Petereit,et al.  Effects of treatment duration during concomitant chemoradiation therapy for cervical cancer. , 2013, International journal of radiation oncology, biology, physics.

[6]  P. Disaia,et al.  Outcomes of high-dose-rate interstitial brachytherapy in the treatment of locally advanced cervical cancer: long-term results. , 2013, International journal of radiation oncology, biology, physics.

[7]  L. Mell,et al.  The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy , 2013, Cancer.

[8]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[9]  L. Tan,et al.  Long-term survival and late toxicity after chemoradiotherapy for cervical cancer--the Addenbrooke's experience. , 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

[10]  P. Maisonneuve,et al.  Carcinoma of the cervix uteri , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[11]  Bengt K Lind,et al.  Influence of overall treatment time and radiobiological parameters on biologically effective doses in cervical cancer patients treated with radiation therapy alone , 2004, Acta oncologica.

[12]  Mitchell Morris,et al.  Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Tierney,et al.  A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  K. Ogawa,et al.  Combination external beam radiotherapy and high-dose-rate intracavitary brachytherapy for uterine cervical cancer: analysis of dose and fractionation schedule. , 2003, International journal of radiation oncology, biology, physics.

[15]  P. Grigsby,et al.  Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. , 1995, International journal of radiation oncology, biology, physics.

[16]  J. Sham,et al.  Dose-tumor response of carcinoma of cervix: an analysis of 594 patients treated by radiotherapy. , 1993, Gynecologic oncology.

[17]  A. Fyles,et al.  The effect of treatment duration in the local control of cervix cancer. , 1992, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[18]  L. Yeh,et al.  Late toxicities in concurrent chemoradiotherapy using high-dose-rate intracavitary brachytherapy plus weekly cisplatin for locally advanced cervical cancer: a historical cohort comparison against two previous different treatment schemes. , 2010, European Journal of Gynaecological Oncology.

[19]  J. Thigpen.  Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group (GOG) trials , 2008 .

[20]  P. Grigsby,et al.  Carcinoma of the uterine cervix. II. Lack of impact of prolongation of overall treatment time on morbidity of radiation therapy. , 1996, International journal of radiation oncology, biology, physics.